Focus On Sites

By working with a range of capable sites, we can reach at-risk populations, bring interventions to those who need it most and address public health issues around the globe.

Sites Worldwide
Partnering With Sites
Site and Investigator Spotlight

WE HAVE RELATIONSHIPS WITH SITES WORLDWIDE

Our database of research-ready sites includes approximately 2,800 sites worldwide, with experience spanning all clinical trial phases, infectious and non-communicable diseases as well as pediatric and adult populations.

Are you a site interested in being considered for future studies with FHI Clinical?

Complete the form, and we will contact you to arrange a formal introduction with the FHI Clinical team for further evaluation of your site.

I'm interested in partnering on future studies

WE PARTNER WITH SITES

Our relationships with sites are built on our shared investment in their sustainability, helping sites develop and maintain research capacity to be able to address public health issues around the globe.
Consistent site activity through additional research opportunities
Additional financial support
Increased independence and sustainability
Research sites can express their interest in being included in FHI Clinical’s internal database via multiple avenues including:
  • The FHI Clinical website and social media
  • Meeting FHI Clinical staff in person via a conference or other event
  • Networking and referrals to FHI Clinical
FHI Clinical’s staff vet interested institutions to make sure they align with our company goals and standards. Then, if the FHI Clinical team moves forward with an institution, the following occurs:
  1. A survey is sent to the institution, to collect details such as (but not limited to) clinical research experience, disease experience and prevalence, phase and population experience, lab capabilities and contact information.
  2. FHI Clinical uses the survey information to aid with designing feasibility strategies and site lists for future sponsored studies
  3. Once an institutional profile has been created, FHI Clinical maintains regular contact with these institutions. This ensures that both parties have current and accurate information about each other’s relevant capacity and bandwidth.
  4. Sites in the database may also provide insight on protocol design and recruitment strategies to ensure both FHI Clinical and the sponsor have accurate real-world information.

SITE AND INVESTIGATOR SPOTLIGHT

Each quarter, we shine the light on one of the sites or investigators in our database.
This Spotlight introduces Flourish Research, headquartered in New York, NY, and with sites in locations throughout the United States. We have partnered with the Flourish Research team and sites for years, and we continue to work together to build awareness of clinical research in underserved communities across the United States.

We began working with FHI Clinical at the site level before the formation of Flourish and have enjoyed the free flow of collaboration and communication between our companies. One of our early study successes from the FHI Clinical team resulted in Flourish achieving 348% of the original recruitment goal. We attribute that success to our two organizations being aligned in our values, such as working toward reaching underserved communities by building awareness of research opportunities. FHI Clinical has a true commitment to long-term site engagement, and we appreciate the structured, consistent communication plan and find the entire FHI Clinical team to be knowledgeable and responsive to their site partners' needs.

— Lele Simmons, VP, Strategic Partnerships, Flourish Research

About Flourish

  • Founded in 2021
  • Clinical Trials of Texas (CTT): the platform site for Flourish, followed by acquisitions of other best-in-class sites
  • Wholly owned clinical trial sites with access to diverse populations
  • Vision: Advancing the health and wellness of society through clinical trials
Flourish Research is headquartered in New York, NY, with clinical research sites and a team of highly experienced investigators located in Alabama, Florida, Illinois, North Carolina, Pennsylvania and Texas. The company uses centralized processes for study feasibility, budgets and contracts, each with a single point of contact.
Thought leaders
Therapeutic areas of focus
  • Cardiovascular diseases
  • Metabolic diseases
  • Central nervous system (CNS) diseases and conditions
  • Infectious diseases (vaccines)
Other research experience
  • Dermatology
  • Early phase
  • Gastroenterology
  • Infectious diseases (treatments; including COVID-19)
  • Men’s health
  • Musculoskeletal
  • Nephrology
  • Nutrition
  • Pain management
 
  • Pediatrics
  • Pulmonology/respiratory
  • Radiological imaging
  • Rheumatology
  • Sleep disorders
  • Urology
  • Vascular medicine
  • Women’s health
Capabilities
  • In-house PBMC services at four labs
  • San Antonio, TX
  • Chicago/Andersonville, IL
  • Winter Park, FL
  • Miami, FL
  • Facilities for next-generation treatments, such as cannabis and psychedelics
  • Recruitment and enrollment of diverse populations
 
  • Early-phase studies
  • Three early phase locations (FL and TX) with 62 beds total (40 inpatient beds)
  • Outpatient Phase 1 trial experience at seven locations
  • First-in-human studies
  • Single ascending dose (SAD)/multiple ascending dose (MAD) studies
  • Insulin challenges
  • Glucose challenges
  • Glucose/insulin manipulation
  • Lumbar punctures
  • Infusions
  • Certified FibroScan techs
  • Bioequivalence
  • Cardiac telemetry
  • Vaccines

more spotlights

Focus on Sites
Featured_1280x720_Kenya_20230627

Lucas Tina, MD, MPH; VIBRI and KEMRI

Kenya

Dr. Lucas Tina is affiliated with the Victoria Biomedical Research Institute (VIBRI) and Kenya Medical Research Institute (KEMRI) in Kisumu, Kenya. Dr. Tina serves as a Scientific Advisory Expert for FHI Clinical, and VIBRI and KEMRI are listed in FHI Clinical’s database of research sites.
Read more
Focus on Sites
Featured_1280x720_Zimbabwe_20230627

Tariro Makadzange, MD, PhD; Charles River Medical Group, Pvt, Ltd (CRMG)

Zimbabwe

Tariro Makadzange, MD, PhD, is the Executive Director and Founder of Charles River Medical Group, Pvt, Ltd (CRMG), in Harare, Zimbabwe. CMRG is listed in FHI Clinical’s database of research sites.
Read more
Focus on Sites
Featured_1280x720_SiteDRC_SiteDRC_SiteDRC

Nsengi Ntamabyaliro, MD, MSc; UPC-PV, University of Kinshasa

Democratic Republic of the Congo (DRC)

FHI Clinical has worked with Nsengi Ntamabyaliro, MD, MSc, from the Unit of Clinical Pharmacology and Pharmacovigilance (UPC-PV), University of Kinshasa, in Kinshasa, Democratic Republic of the Congo (DRC), on Phase 3 and 4 trials since 2007, at which time there was a focus on research capacity development in the DRC.
Read more